Molecular Response has the world’s largest bank of viable cryopreserved tumor cells. The bank contains more than 144,000 tumor specimens, covering 25 tissue types and 76 clinical diagnoses (Table 1). Each of the specimens contains viable tumor cells that were cryfrozen as single cell suspensions for culture.
The bank was collected over the past 20 years from a US population, with matched histology/path review and associated ex-vivo treatment data for each specimen.
Additionally, each specimen has matching DNA, RNA and protein available for screening targets of interest in order to identify particular tumor cases for subsequent studies, including ex vivo and in vivo drug screens.
INDICATIONS
The Molecular Response Tumor Bank features tumors from virtually all known–common and rare–cancer indications. Major cancer types such as breast, lung, colon, and ovarian average >10,000 specimens per indication. Less common cancers are also prominently featured, including small cell lung and neuroendocrine, for example. See Table 1A and 1B for a complete list of tumor types.
DRUG RESPONSE DATA
Each of the specimens in the tumor bank has been profiled against a panel of drugs ex vivo, and levels of resistance recorded; we leverage the drug resistance data to select tumor cells of interest for our partners’ drug treatment studies and molecular marker discovery. See Table 2 for a complete list of drugs screened per indication.
APPLICATIONS
Tumor Bank Applications:
- ex vivo treatment studies
- in vivo xenograft studies
- Predictive marker discovery/development
- Frequency/prevalence screens for target
- Target identification
Table 1A. Tumor specimens by tissue type:
| Bladder
Brain Breast Cervix Colon Endocrine GI Head & Neck Leukemia Liver Lung (non small cell) Lung (small cell) Lymphoid Lymphoma Mesothelioma |
Myeloma
Nervous Neuroendocrine Oral Other Ovarian Pancreas Prostate Renal Sarcoma Skin Squamous carcinoma Testicular Uterus |
Table 1B. Tumor specimens by clinical diagnosis:
| Acute lymphocytic leukemia
Acute non-lymphocytic leukemia Adrenal carcinoma Anemia, pancytopenia Appendiceal carcinoma Basal cell carcinoma Benign Bladder carcinoma Brain tumor Breast carcinoma Carcinoid tumor Cervical carcinoma Choriocarcinoma Chronic lymphocytic leukemia Chronic myelogenous leukemia CNS tumor Colon carcinoma Desmoplastic small round cell Endometrial carcinoma Esophageal carcinoma Ewing’s sarcoma Fallopian tube carcinoma Gallbladder carcinoma Gastrointestinal stromal tumor Granulosa cell tumor Hairy cell leukemia |
Hodgkin’s lymphoma
Kidney carcinoma Liver carcinoma Lymphoproliferative disorder Malignant fibrous histiocytoma Malignant melanoma Malignant mesothelioma Merkel cell carcinoma Miscellaneous tumor Mixed mullerian tumor Multiple myeloma Myelodysplastic syndromes Neuroblastoma Neuroendocrine tumor Non-Hodgkin’s lymphoma Non-small cell lung cancer Osteosarcoma Ovarian (Small Cell) Ovarian carcinoma Ovarian germ cell tumor Ovarian LMP Ovarian sarcoma Pancreatic carcinoma Parotid gland carcinoma Peritoneal carcinoma Primitive neuroectodermal |
Prostate carcinoma
Pseudomyxoma peritonei R/O malignant lymphoma Salivary gland carcinoma Sarcoma Small cell carcinoma Small intestine carcinoma Squamous carcinoma of cervix Squamous carcinoma of H&N Squamous cell carcinoma Squamous cell carcinoma, UPS Squamous cell vulva Stomach carcinoma Testicular germ cell tumor Thymoma Thyroid carcinoma Transitional cell kidney Unknown primary site Unknown primary site, gyn Unknown, not provided Uterine sarcoma Vaginal carcinoma Waldenstrom macroglobulinemia Wilm’s tumor |
| ANLL 1. Daunorubicin
2. Cytarabine 3. Mitoxantrone 4. Idarubicin 5. Carboplatin 6. Etoposide 7. Fludarabine 8. Topotecan
1. Carboplatin 2. Taxol 3. Navelbine 4. Etoposide 5. Gemcitabine 6. Topotecan 7. Cisplatin 8. Taxotere
1. Interleukin 2 2. Alpha-Interferon 3. Fluorouracil 4. Gemcitabine 5. Doxil 6. Vinblastine 7. Interferon + Vinblastine 8. Mitomycin C 9. Cyclophosphamide |
Breast 1. Doxorubicin
2. Cyclophosphamide 3. Taxol 4. Fluorouracil 5. Navelbine 6. Taxotere 7. Gemcitabine 8. Cisplatin 9. Capecitabine
1. Cisplatin 2. Temozolomide 3. Vinblastine 4. Taxotere 5. Navelbine 6. Gemcitabine 7. Navelbine + Taxotere 8. Alpha-Interferon 9. Carmustine
1. Doxorubicin 2. Ifosfamide 3. Temozolomide 4. Cisplatin 5. Taxotere 6. Gemcitabine 7. Topotecan |
Colorectal 1. 5 FU + Leucovorin
2. Irinotecan 3. 5 FU + Irinotecan 4. Oxaliplatin 5. Topotecan 6. Capecitabine 7. Floxuridine 1. Cisplatin 2. Taxol 3. Doxorubicin 4. Ifosfamide 5. Etoposide 6. Cyclophosphamide 7. Topotecan
1. Cyclophosphamide 2. Doxorubicin 3. Vincristine 4. Dexamethasone 5. Etoposide 6. Bleomycin 7. Cytarabine |
CLL 1. Fludarabine
2. Cyclophosphamide 3. Dexamethasone 4. Doxorubicin 5. Vincristine 6. Melphalan 7. Cladribine 1. Melphalan 2. Vincristine 3. Doxorubicin 4. Dexamethasone 5. Cyclophosphamide 6. Carmustine 7. Etoposide 8. Alpha-Interferon
1. Cisplatin 2. Ifosfmide 3. Etoposide 4. Fluorouracil 5. Cyclophosphamide 6. Doxorubicin 7. Taxol |
Ovarian 1. Carboplatin
2. Taxol 3. Topotecan 4. Doxil 5. Etoposide 6. Gemcitabine 7. Taxotere 8. Cisplatin 9. Cisplatin + Gemcitabine 10. Cyclophosphamide
1. Fluorouracil 2. Mitomycin C 3. Doxorubicin 4. Cisplatin 5. Etoposide 6. Gemcitabine 7. Taxol
1. Cisplatin 2. Doxorubicin 3. Fluorouracil 4. Cyclophosphamide 5. Taxol 6. Topotecan 7. Etoposide |